Home Mainline IPOs Goldline Pharmaceutical IPO
Orion Industries logo

Goldline Pharmaceutical IPO

Open Sme
BSE 12 May - 14 May 2026
Goldline Pharmaceutical Limited IPO is a book build issue of 12 Cr. The issue is entirely a fresh issue of 2562000 shares aggregating to 11 Cr. Goldline Pharmaceutical Limited IPO opened for subscription on May 12, 2026 and closed on May 14, 2026. The allotment for the this IPO was finalized on May 15, 2026. IPO was listed on NSE and BSE on May 19, 2026. Goldline Pharmaceutical Limited IPO is set issue price band at ₹41 to ₹43 per share.

Current GMP

₹15 (+34.88%)

Price Band

₹ 41 – 43

Lot Size

3000

Issue Size

₹12 Cr

Minimum Investment

₹258000 (6000 Shares)

Listing Date

19 May 2026

Subscription

840.81x

About the Company

Goldline Pharma comprises 42 products catering to a wide range of medical specialties, including Physicians, Orthopedics, ENT, Chest Physicians, General and Specialty Surgery, Gastroenterology, Neurology, and Urology. This division focuses on delivering quality formulations for acute and chronic healthcare requ

Go

Goldline Cardinal includes 54 products developed for the specialty healthcare segment. The division primarily serves Physicians, Diabetologists, Endocrinologists, Cardiologists, and General Physicians, offering therapies focused on lifestyle

Goldline Aayushman

Goldline Aayushman consists of 18 products designed for Pediatricians, Child Specialists, Neonatologists, and General Practitioners. The division focuses on pediatric and neonatal healthcare solutions aimed at supporting child wellness and development.

Goldline InLife

Goldline InLife offers 22 products catering to Intensivists, Critical Care Consultants, Super Specialty Surgeons, and Physicians. The division is focused on critical care and specialty treatments required in advanced healthcare settings and hospitals.

Goldline Wellness

Goldline Wellness comprises 10 products dedicated to supportive care in cancer therapy and patient wellness management. The division emphasizes improving patient care and quality of life during treatment.

The company follows an asset-light business model and does not manufacture pharmaceutical products directly. Instead, it collaborates with third-party manufacturers who produce medicines based on the company’s market research, product specifications, and quality standards, while ensuring compliance with applicable pharmaceutical regulations.

All products are marketed and sold under the “Goldline” brand through a well-established distribution network comprising distributors, retailers, and wholesalers. The company currently partners with 15 manufacturers and 7 distributors to ensure efficient supply chain management and market reach.

In addition to pharmaceutical marketing and distribution, the company also supports hospitals and healthcare institutions through procurement assistance and material supply services.

Goldline Pharmaceuticals has established its presence across multiple Indian states, including Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar.

Promoters

  1. Amol Laxmikant Mujumdar
  2. Swapan Premprakash Khandelwal 
Promoters Holding

Holding Pre Issue

79.70%

Holding Post Issue

0.00%

Objects of the Issue

The Company proposes to utilise the Net Proceeds from the Issue towards the following objects.

  1. Prepayment or repayment of all or a portion of certain outstanding borrowings availed by our company 
  2. General corporate purposes

Address / Contact Info

Goldline Pharmaceutical Ltd. Address
103, F-1, Leela Apartment, Shilpa HSG Society,
Near Saptagiri Nagar, Shanidham,
Narendra Nagar,
Nagpur, Maharashtra, 440015
Email: info@goldlinepharma.in
Tel: +91 712 278 6666
Website:http://www.goldlinepharma.in/

IPO Snapshot

Face Value₹10 per share
Price Band₹ 41 – 43
Lot Size3000
Issue TypeBook-building IPO
Sale TypeFresh Capital
Fresh Issue₹ 11.00 Cr
Offer for Sale₹ 0.00 Cr
Total Issue Size₹ 12.00 Cr
Listing AtBSE
IndustryPharmaceutical & Drugs
SectorHealthcare
QIB Quota29.51%
BNII Quota14.1%
SNII Quota7.21%
Retail Quota49.18%

Disclaimer: This data is for informational purposes only and does not constitute investment advice. Figures shown are illustrative sample data.

Frequently Asked Questions

Everything you need to know before applying to an IPO.

Goldline Pharmaceutical IPO is a Book-building IPO worth ₹12 crores. The price band is ₹41 to 43 per share. The IPO opens on Tue, May 12, 2026 and closes on Thu, May 14, 2026. It will be listed on BSE and NSE. Bigshare Services Pvt Ltd is the registrar.

The Goldline Pharmaceutical IPO opens on Tue, May 12, 2026 and closes on Thu, May 14, 2026

Goldline Pharmaceutical IPO Price Band is ₹41 to 43.

Goldline Pharmaceutical IPO lot size is 3000, and the minimum amount required for application is ₹258000.

The minimum investment for Goldline Pharmaceutical IPO is approximately ₹258000 based on the upper price band.

To apply for the Goldline Pharmaceutical IPO, investors can use the ASBA (Application Supported by Blocked Amount) process via their bank's net banking or apply through UPI using a registered broker or trading app. The IPO is available in retail, HNI, and institutional investor categories. Investors must select the lot size, enter bid details within the price band, and submit their application before the IPO closing date of Thu, May 14, 2026. After submission, funds are blocked until the basis of allotment of Goldline Pharmaceutical IPO is finalised.

Goldline Pharmaceutical IPO issue size is ₹12 crores.

Goldline Pharmaceutical IPO allotment date is Sat, Jun 27, 2026.

The registrar for Goldline Pharmaceutical IPO is Bigshare Services Pvt Ltd. Investors can go to Bigshare Services Pvt Ltd website for IPO allotment status, refund processing, and other queries related to Goldline Pharmaceutical IPO through their official website or helpline.

The Goldline Pharmaceutical IPO GMP (Grey Market Premium) is ₹15 as of Tue, May 19, 2026. Based on the upper price band of ₹43 per share, the estimated Goldline Pharmaceutical IPO listing price is ₹58, indicating a potential listing gain of approximately 31% over the issue price.